Ferring Pharmaceuticals today announced the opening of a state-of-the-art global manufacturing hub in Finland for the drug substance of its intravesical non-replicating gene therapy Adstiladrin® (nadofaragene firadenovec-vncg). This represents a significant milestone in Ferring’s
